JP2024508903A5 - - Google Patents

Info

Publication number
JP2024508903A5
JP2024508903A5 JP2023553432A JP2023553432A JP2024508903A5 JP 2024508903 A5 JP2024508903 A5 JP 2024508903A5 JP 2023553432 A JP2023553432 A JP 2023553432A JP 2023553432 A JP2023553432 A JP 2023553432A JP 2024508903 A5 JP2024508903 A5 JP 2024508903A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
haloalkyl
independently
miro1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023553432A
Other languages
English (en)
Japanese (ja)
Other versions
JP7884740B2 (ja
JP2024508903A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/018682 external-priority patent/WO2022216386A2/en
Publication of JP2024508903A publication Critical patent/JP2024508903A/ja
Publication of JP2024508903A5 publication Critical patent/JP2024508903A5/ja
Application granted granted Critical
Publication of JP7884740B2 publication Critical patent/JP7884740B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023553432A 2021-03-04 2022-03-03 T型カルシウムチャネルアンタゴニストおよびその使用 Active JP7884740B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163156806P 2021-03-04 2021-03-04
US63/156,806 2021-03-04
US202163228505P 2021-08-02 2021-08-02
US63/228,505 2021-08-02
PCT/US2022/018682 WO2022216386A2 (en) 2021-03-04 2022-03-03 T-type calcium channel antagonists and uses thereof

Publications (3)

Publication Number Publication Date
JP2024508903A JP2024508903A (ja) 2024-02-28
JP2024508903A5 true JP2024508903A5 (cg-RX-API-DMAC7.html) 2025-03-11
JP7884740B2 JP7884740B2 (ja) 2026-07-06

Family

ID=83545681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023553432A Active JP7884740B2 (ja) 2021-03-04 2022-03-03 T型カルシウムチャネルアンタゴニストおよびその使用

Country Status (10)

Country Link
US (1) US20240190865A1 (cg-RX-API-DMAC7.html)
EP (1) EP4301759A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884740B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230167035A (cg-RX-API-DMAC7.html)
AU (1) AU2022255225A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023016601A2 (cg-RX-API-DMAC7.html)
CA (1) CA3208202A1 (cg-RX-API-DMAC7.html)
IL (1) IL305381A (cg-RX-API-DMAC7.html)
MX (1) MX2023010175A (cg-RX-API-DMAC7.html)
WO (1) WO2022216386A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081653A2 (en) * 2022-10-12 2024-04-18 Acurex Biosciences Corporation Methods of lowering miro2 to treat neurodegenerative diseases
US20260174741A1 (en) * 2022-10-31 2026-06-25 Acurex Biosciences Corporation Methods of reducing miro1 or phosphorylated alpha-synuclein
CN116813444A (zh) * 2023-06-28 2023-09-29 福建凯昕药业有限公司 一种1-溴-4-(1-(三氟甲基)环丙基)苯的制备方法
IT202400013555A1 (it) * 2024-06-13 2025-12-13 Iama Therapeutics S R L Derivati benzoimidazolici come inibitori di nkcc1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610701B2 (en) * 2001-02-09 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
US7875636B2 (en) * 2006-04-12 2011-01-25 Merck Sharp & Dohme Corp. Pyridyl amide T-type calcium channel antagonists
KR20100072266A (ko) * 2007-10-24 2010-06-30 머크 샤프 앤드 돔 코포레이션 헤테로사이클 페닐 아미드 t-형 칼슘 채널 길항제
CA2702126A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
US8987310B2 (en) * 2009-10-30 2015-03-24 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
CN114929242A (zh) * 2019-09-05 2022-08-19 小利兰·斯坦福大学托管委员会 修饰线粒体功能的方法和化合物

Similar Documents

Publication Publication Date Title
TWI665178B (zh) 作為化療劑的β-取代的β-氨基酸和類似物及其應用
JP6218260B2 (ja) Jak阻害剤としてのアミノピリミジニル化合物
JP2008513498A5 (cg-RX-API-DMAC7.html)
JP2008513516A5 (cg-RX-API-DMAC7.html)
JP2005519908A5 (cg-RX-API-DMAC7.html)
RU2009147708A (ru) Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842
RU2009137390A (ru) Аминопиримидины, пригодные в качестве ингибиторов протеинкиназ
JP2020502092A5 (cg-RX-API-DMAC7.html)
RU2009137779A (ru) Композиции, содержащие (s)-2-амино-1-(4-хлорфенил)-1-[4-(1н-пиразол-4-ил)фенил]этанол, в качестве модуляторов протеинкиназ
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2019505529A5 (cg-RX-API-DMAC7.html)
TWI674263B (zh) 用於治療寄生蟲疾病之化合物及組合物
RU2010129929A (ru) Производные 5-оксо-3-пирролидинкарбоксамида в качестве модуляторов р2х7
JP2019535723A5 (cg-RX-API-DMAC7.html)
JP2017510595A5 (cg-RX-API-DMAC7.html)
JP2017502967A5 (cg-RX-API-DMAC7.html)
JP2024160326A (ja) Eaat2活性化因子およびその使用方法
JP2011530607A5 (cg-RX-API-DMAC7.html)
JP2020519659A5 (cg-RX-API-DMAC7.html)
AU2022244224B9 (en) Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors
JP2018531995A5 (cg-RX-API-DMAC7.html)
JP2024511057A5 (cg-RX-API-DMAC7.html)
JP2024511997A5 (cg-RX-API-DMAC7.html)
JP2019535715A5 (cg-RX-API-DMAC7.html)
CN115867562A (zh) Akt3调节剂